glp-1 receptor agonist antipsychotic weight gain study Efficacy and Safety of Agonists for the Management of Antipsychotic-Induced GLP-1 Agonists For Obesity In
Description
Oral semaglutide has been approved and recently marketed in Spain following evidence from the Phase 3 clinical trial program Peptide InnOvatioN for Early diabEtes tReatment (PIONEER)
Semaglutide administered subcutaneously lowers HbA1c more than any other long-acting medication
10.1016/j.nefro.2022.07.008 [DOI] [PubMed] [Google Scholar] 27
The anti-inflammatory and immunological properties of SGLT-2 inhibitors
